Press Brief

6:22
Integrated sequencing in AML/MDS reveals prognostic constellations
Ilaria Iacobucci
7:02
BCL11A as therapeutic target in SCD: gene therapy trial
David Williams
6:36
CANDOR results reveal new regimen for RRMM: KdD
Saad Usmani
4:36
Promising results for blinatumomab in younger relapsed B-ALL
Patrick Brown
6:28
Practice-changing potential from Cardinal: sutimlimab in CAD
Alexander Röth
6:34
BCMA-CD38 bispecific CAR-T cells in R/R MM
Yu Hu
7:42
CARTITUDE-1 results: CAR-T against BCMA in R/R MM
Deepu Madduri
9:26
Mosunetuzumab induces CR in B-NHL R/R to CAR-T
Stephen Schuster
8:54
FT596: iPSC-derived CAR-NK cells with engineered persistence for B-cell malignancies
Bahram Valamehr
12:38
Hu5F9 plus rituximab to overcome resistance in refractory lymphoma
Mark Roschewski
10:21
ASCEND-ing results: acalabrutinib is well-tolerated and highly effective in R/R CLL
Paolo Ghia
8:11
Venetoclax with bortezomib/dexamethasone: phase 3 BELLINI results in R/R myeloma
Shaji Kumar
5:40
Data from the Phase 3 CASSIOPEIA trial: D-VTd vs. VTd
Philippe Moreau
2:01
EHA 2019 program: insights from the Chair of the Scientific Program Committee
Maria-Victoria Mateos
9:28
New double targeting approach for beta-thalassemia
Antonella Nai
9:38
Imetelstat provides durable transfusion independence in lower risk MDS group
Pierre Fenaux
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals